SCHEMBL15613566

SCHEMBL15613566

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(C(C)(C)C)c5ncnc(N)c45)cc3)c2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ HTT P42858 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ SRC P12931 18/20 0.51
▸ ABL1 P00519 10/20 0.51
▸ EGFR P00533 4/20 0.51
▸ KDR P35968 3/20 0.51
▸ RIPK2 O43353 2/20 0.51
▸ LCK P06239 2/20 0.51
▸ FYN P06241 2/20 0.51
▸ YES1 P07947 2/20 0.51
▸ LYN P07948 2/20 0.51
▸ PDGFRA P16234 2/20 0.51
▸ PRKACA P17612 2/20 0.51
▸ FRK P42685 2/20 0.51
▸ MAPK9 P45984 2/20 0.51
▸ CSNK1A1 P48729 2/20 0.51
▸ CSNK1D P48730 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886186 0.90 KDM4E (0.56) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL15613749 0.89 NUDT14 (0.56) SRCABL1EGFRKDRBTK
SCHEMBL15613501 0.88 MAPK1 (0.46) KDM4ESRCABL1EGFRLCK
SCHEMBL15613680 0.87 SRC (0.56) SRCABL1EGFRKDRLCK
SCHEMBL15613534 0.86 BTK (0.48) SRCABL1EGFRKDRLCK
SCHEMBL15613683 0.86 BTK (0.59) SRCABL1EGFRKDRLCK
SCHEMBL15613666 0.86 KDM4E (0.57) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL15613521 0.86 SRC (0.47) SRCABL1EGFRKDRLCK
SCHEMBL15613591 0.85 SRC (0.46) SRCABL1EGFRKDRBTK
SCHEMBL15613671 0.85 BTK (0.51) SRCABL1EGFRKDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK KDM4E 1338/4885ALDH1A1 4521/4885LMNA 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback